Thumỹ Phan for STAT

STAT+ | Will bargain-basement telehealth visits help pharma drive drug scripts?

Cheap telehealth visits advertised by pharma could steer patients toward expensive branded drugs, raising concerns about potential anti-kickback violations.

By Katie Palmer

STAT+ | Publicly, Kennedy embraces a more moderate MAHA

Across seven congressional hearings, RFK Jr. lightened his messaging on vaccines and pesticides, but the MAHA impact on policy continues to be felt.

By Daniel Payne and Chelsea Cirruzzo

STAT+ | Trump’s boosting of psychedelics, cannabis signal a new era in GOP drug policy

The Trump administration, in a stark departure from the "Just Say No" era, is funding psychedelics research and rescheduling marijuana.

By Lev Facher

Library of Congress

Opinion: Dropping the flu vaccine requirement puts U.S. military readiness at risk

Retired general — also a doctor — says the secretary of defense erred in dropping annual flu shot requirement: "Asserting that flu poses no risk is untrue."

By Paul Friedrichs

STAT+ | Can Erasca be biotech’s next big thing? We’ll see

In this week's edition of "Adam's Biotech Scorecard," Adam looks at a company seeking to outdo Revolution Medicines in cancer.

By Adam Feuerstein

Opinion: Kennedy’s new silence on vaccines is political — and it won’t last

Kennedy’s lull in anti-vaccine rhetoric and action should not be mistaken for a durable pivot in federal vaccine policy.

By Will Walters and Richard Hughes IV

Adobe

Heart’s beat may help it beat cancer, mouse research suggests

Researchers say constant pressure from heart beat creates environment hostile to cancer. Findings could inspire massage-type treatments.

By Anil Oza

STAT+ | Legislatures in Colorado and Virginia resist moves to constrain drug affordability boards

Attempts to constrain the boards come amid ongoing debate over the cost of prescription drugs and how to address the problem.

By Ed Silverman